Arcutis Biotherapeutics (ARQT) Cash & Current Investments (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Cash & Current Investments of $189.5 million for Q1 2026, up 30.18% year-over-year from $145.6 million in Q1 2025, and down 14.23% quarter-over-quarter from $221.0 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Cash & Current Investments (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $189.5 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 30.18% year-over-year to $189.5 million; the TTM figure through Mar 2026 stood at $189.5 million (up 30.18% YoY), while the FY2025 annual figure was $221.0 million, down 3.06% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $189.5 million, down from $221.0 million in the prior quarter.
- The five-year high for Cash & Current Investments was $396.7 million in Q3 2022, with the low at $118.4 million in Q2 2025.
- The 5-year median for Cash & Current Investments is $221.0 million (2025), against an average of $232.3 million.
- The sharpest annual moves came in 2023 and 2024: Cash & Current Investments sank 69.61% in 2023, then soared 174.23% in 2024.
- Arcutis Biotherapeutics' Cash & Current Investments stood at $357.2 million in 2022, then sank by 48.38% to $184.4 million in 2023, then climbed by 23.63% to $228.0 million in 2024, then dropped by 3.06% to $221.0 million in 2025, then slipped by 14.23% to $189.5 million in 2026.
- Business Quant data shows ARQT's Cash & Current Investments at $189.5 million in Q1 2026, $221.0 million in Q4 2025, and $191.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 836.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 238.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 238.55 Mn |
| Mar 31, 2026 | 189.55 Mn |
| Dec 31, 2025 | 220.98 Mn |
| Sep 30, 2025 | 191.07 Mn |
| Jun 30, 2025 | 118.38 Mn |
| Mar 31, 2025 | 145.60 Mn |
| Dec 31, 2024 | 227.96 Mn |
| Sep 30, 2024 | 330.56 Mn |
| Jun 30, 2024 | 278.78 Mn |
| Mar 31, 2024 | 214.37 Mn |
| Dec 31, 2023 | 184.39 Mn |
| Sep 30, 2023 | 120.54 Mn |
| Jun 30, 2023 | 164.46 Mn |
| Mar 31, 2023 | 251.90 Mn |
| Dec 31, 2022 | 357.18 Mn |
| Sep 30, 2022 | 396.65 Mn |
| Jun 30, 2022 | 282.17 Mn |
| Mar 31, 2022 | 275.01 Mn |
| Dec 31, 2021 | 292.15 Mn |
| Sep 30, 2021 | 367.27 Mn |